Menu
Back to Archived Journals » Hypoxia » Volume 4
The Three "Musketairs" – Lasker Prize 2016 goes to the protagonists of hypoxia research
Authors Wenger RH , Katschinski DM
Received 1 November 2016
Accepted for publication 1 November 2016
Published 25 November 2016 Volume 2016:4 Pages 161—162
DOI https://doi.org/10.2147/HP.S126290
Checked for plagiarism Yes
Roland H Wenger,1 Dörthe M Katschinski2
1Institute of Physiology, University of Zurich, Zurich, Switzerland; 2Institute of Cardiovascular Physiology, Georg-August University Göttingen, Göttingen, Germany
Who does not know them? One bearded like a pirate, one knighted by the Queen, and one of noble spirit. United in the fight for truth and honor! No, this is not about Alexandre Dumas’ characters Porthos, Athos, and Aramis, well-known from the famous novel The Three Musketeers.1 This is about the most recent awardees of the Albert Lasker Basic Medical Research Award, the three protagonists of hypoxia research Gregg Semenza, Sir Peter Ratcliffe, and Bill Kaelin. The recent bestowal of the Lasker Prize is just another hallmark in a long list of recognitions of the major achievements by these three outstanding colleagues. What major victories in the battle against the unknowns in hypoxia research did our three heroes achieve?
Disclosure
The authors report no conflicts of interest in this work.
References
Dumas A. The Three Musketeers. Abingdon-on-Thames: George Routledge and Sons, Ltd.; 1922. | ||
Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol. 1992;12:5447–5454. | ||
Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA. 1995;92:5510–5514. | ||
Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA. 1993;90:4304–4308. | ||
Maxwell PH, Pugh CW, Ratcliffe PJ. Inducible operation of the erythropoietin 3’ enhancer in multiple cell lines: evidence for a widespread oxygen-sensing mechanism. Proc Natl Acad Sci USA. 1993;90:2423–2427. | ||
Wenger RH. Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. FASEB J. 2002;16:1151–1162. | ||
Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399:271–275. | ||
Shen C, Beroukhim R, Schumacher SE, et al. Genetic and functional studies implicate HIF1α as a 14q kidney cancer suppressor gene. Cancer Discov. 2011;1:222–235. | ||
Ivan M, Kondo K, Yang H, et al. HIFa targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001;292:464–468. | ||
Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001;292:468–472. | ||
Epstein AC, Gleadle JM, McNeill LA, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 2001;107(1):43–54. | ||
Dove Medical Press encourages responsible, free and frank academic debate. The content of the Hypoxia ‘Editorial’ section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Hypoxia editors. While all reasonable steps have been taken to confirm the content of each Editorial, Dove Medical Press accepts no liability in respect of the content of any Editorial, nor is it responsible for the content and accuracy of any Editorial. |
© 2016 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.